vs
Assertio Holdings, Inc.（ASRT）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
Assertio Holdings, Inc.的季度营收约是Lakeside Holding Ltd的1.9倍（$13.5M vs $7.0M），Lakeside Holding Ltd同比增速更快（95.0% vs -57.9%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
ASRT vs LSH — 直观对比
营收规模更大
ASRT
是对方的1.9倍
$7.0M
营收增速更快
LSH
高出153.0%
-57.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $7.0M |
| 净利润 | — | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | -86.7% | -21.3% |
| 净利率 | — | -22.6% |
| 营收同比 | -57.9% | 95.0% |
| 净利润同比 | — | 18.7% |
| 每股收益（稀释后） | $-4.54 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTLSH
| Q4 25 | $13.5M | $7.0M | ||
| Q3 25 | $49.5M | $6.1M | ||
| Q2 25 | $29.2M | $6.3M | ||
| Q1 25 | $26.5M | $3.8M | ||
| Q4 24 | $32.2M | $3.6M | ||
| Q3 24 | $29.2M | $4.1M | ||
| Q2 24 | $31.1M | — | ||
| Q1 24 | $32.4M | — |
净利润ASRTLSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $11.4M | $-1.4M | ||
| Q2 25 | $-16.4M | $-893.1K | ||
| Q1 25 | $-13.5M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-2.9M | $-1.3M | ||
| Q2 24 | $-3.7M | — | ||
| Q1 24 | $-4.5M | — |
毛利率ASRTLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ASRTLSH
| Q4 25 | -86.7% | -21.3% | ||
| Q3 25 | 23.2% | -20.8% | ||
| Q2 25 | -27.5% | -8.9% | ||
| Q1 25 | -50.0% | -28.2% | ||
| Q4 24 | -41.9% | -55.6% | ||
| Q3 24 | -10.4% | -32.5% | ||
| Q2 24 | -11.6% | — | ||
| Q1 24 | -13.4% | — |
净利率ASRTLSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | 23.1% | -22.2% | ||
| Q2 25 | -56.0% | -14.2% | ||
| Q1 25 | -51.1% | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | -10.0% | -32.7% | ||
| Q2 24 | -11.8% | — | ||
| Q1 24 | -13.9% | — |
每股收益（稀释后）ASRTLSH
| Q4 25 | $-4.54 | $-0.08 | ||
| Q3 25 | $0.11 | $-0.09 | ||
| Q2 25 | $-0.17 | $-0.11 | ||
| Q1 25 | $-0.14 | $-0.14 | ||
| Q4 24 | $-3.28 | $-0.26 | ||
| Q3 24 | $-0.03 | $-0.18 | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.05 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $94.0M | $12.2M |
| 总资产 | $267.0M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资ASRTLSH
| Q4 25 | $63.4M | $1.6M | ||
| Q3 25 | $93.4M | $4.5M | ||
| Q2 25 | $98.2M | $5.0M | ||
| Q1 25 | $87.3M | $1.5M | ||
| Q4 24 | $100.1M | $1.1M | ||
| Q3 24 | $88.6M | $2.7M | ||
| Q2 24 | $88.4M | — | ||
| Q1 24 | $80.7M | — |
总债务ASRTLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTLSH
| Q4 25 | $94.0M | $12.2M | ||
| Q3 25 | $105.8M | $7.0M | ||
| Q2 25 | $93.3M | $2.8M | ||
| Q1 25 | $108.5M | $749.8K | ||
| Q4 24 | $121.1M | $1.6M | ||
| Q3 24 | $130.5M | $3.6M | ||
| Q2 24 | $132.2M | — | ||
| Q1 24 | $134.5M | — |
总资产ASRTLSH
| Q4 25 | $267.0M | $24.3M | ||
| Q3 25 | $319.8M | $18.6M | ||
| Q2 25 | $273.8M | $14.4M | ||
| Q1 25 | $286.4M | $9.9M | ||
| Q4 24 | $284.7M | $9.8M | ||
| Q3 24 | $276.0M | $10.8M | ||
| Q2 24 | $279.4M | — | ||
| Q1 24 | $282.0M | — |
负债/权益比ASRTLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASRTLSH
| Q4 25 | $-30.0M | $-453.5K | ||
| Q3 25 | $-4.8M | $-4.0M | ||
| Q2 25 | $19.1M | $-483.7K | ||
| Q1 25 | $-12.5M | $-238.3K | ||
| Q4 24 | $11.5M | $-530.2K | ||
| Q3 24 | $-35.0K | $-1.4M | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $7.5M | — |
自由现金流ASRTLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ASRTLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ASRTLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ASRTLSH
| Q4 25 | — | — | ||
| Q3 25 | -0.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
